DHE45 IV
Selected indexed studies
- Intravenous Lidocaine for Acute Pain: A Systematic Review. (Pharmacotherapy, 2018) [PMID:30303542]
- Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations. (J Pain Res, 2020) [PMID:32431533]
- The Pharmacokinetics of Drugs Delivered to the Upper Nasal Space. (Pharmaceut Med, 2023) [PMID:37537422]
_Worker-drafted node — pending editorial review._
Connections
DHE45 IV is a side effect of
Sources
- Inhaled drug therapy development for the treatment of migraine. (2016) pubmed
- Intravenous Lidocaine for Acute Pain: A Systematic Review. (2018) pubmed
- Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations. (2020) pubmed
- The Pharmacokinetics of Drugs Delivered to the Upper Nasal Space. (2023) pubmed
- Tolerability of repetitive dihydroergotamine infusions paired with an adjustment in preventive treatment strategy in chronic headache disorders in children and youth. (2025) pubmed
- Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review. (2016) pubmed
- Treatment of status migrainosus. (2001) pubmed
- Migraine: pathophysiology, pharmacology, treatment and future trends. (2003) pubmed
- Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. (1997) pubmed
- IV dihydroergotamine therapy for migraine treatment. (1988) pubmed